Announcements Trials
Browse Landscape

Phase

Phase 2 135Phase 3 45Phase 1/2 44Phase 1 29Phase NA 9Phase 4 4Phase EARLY_PHASE1 3Phase 2/3 2

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 4Myeloid 3Lymphoid 3Plasma cell 2Classical hematology 2Sarcoma 1Other solid neoplasm 1Genitourinary 1Dermatologic 1CNS 1

Conditions

Multiple Myeloma 2

Interventions

Dexamethasone 8daratumumab 5Lenalidomide 5Bortezomib 5Trimethoprim, Sulfamethoxazole Drug Combination 4Thalidomide 4Cyclophosphamide 4gamma-Globulins 3Ciprofloxacin 3carfilzomib 2Melphalan 2Immunoglobulins, Intravenous 2Calcium Dobesilate 2Amoxicillin-Potassium Clavulanate Combination 2trametinib 1tanespimycin 1pomalidomide 1pazopanib 1fludarabine 1dabrafenib 1cobimetinib 1Whole-Body Irradiation 1Vemurafenib 1Stem Cell Transplantation 1Rivaroxaban 1Radiotherapy 1Radiation 1Pharmaceutical Preparations 1Mesna 1MAGEA3 protein, human 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Melphalan × Plasma cell × Clear all
NCT00177047 2021-11-09

Autologous Transplant for Multiple Myeloma

Masonic Cancer Center, University of Minnesota

Phase 2/3 Completed
363 enrolled 25 charts
Plasma cell

Multiple Myeloma

NCT03385096 2020-02-25

Mel vs BUCY+VP-16 Conditioning Regimen for MM Undergoing Auto-HSCT

Nanfang Hospital, Southern Medical University

Phase 2/3 Unknown
122 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡